Cardiac angiosarcoma is the most common primary malignant tumor of the heart, constituting 35-40% of all primary cardiac malignant tumors. Approximately 80% of cases originate from the right atrium and tend to invade the right atrial free wall, interatrial septum, and pericardium. Mean age at diagnosis is 40-50 years with slight male predominance (2:1). It is a rapidly growing, aggressive tumor — most patients have pericardial effusion, metastasis, or both at the time of diagnosis. Emergency presentation with hemorrhagic pericardial effusion and tamponade is common. On MR, the tumor shows heterogeneous signal; T1 hyperintense signal due to hemorrhagic areas ('cauliflower' morphology), irregular borders, and pericardial invasion are characteristic. Prognosis is extremely poor — median survival is 6-12 months.
Age Range
30-70
Peak Age
50
Gender
Equal
Prevalence
Rare
Cardiac angiosarcoma is a high-grade vascular sarcoma arising from malignant transformation of endothelial cells. Tumor cells form irregular, anastomosing vascular channels filled with erythrocytes — this architecture explains the hemorrhagic character of the tumor. Right atrial predilection is attributed to the higher proliferative capacity of endothelial cells in this region and hemodynamic stress, though the exact mechanism is unknown. The tumor rapidly invades myocardium, pericardium, and mediastinal structures — transmural growth extends to the pericardial space creating hemorrhagic effusion. Intratumoral hemorrhage is very common because neovascular channels are structurally fragile, and intratumoral hemorrhage is the main cause of T1 hyperintensity (methemoglobin accumulation). Metastasis is early and aggressive — lungs (60-70%), liver, bone, and brain are the most common metastatic sites. High VEGF expression of the tumor promotes angiogenesis and contributes to rapid growth. UV exposure, vinyl chloride, arsenic, and prior radiotherapy are known risk factors, but most cardiac angiosarcomas have no identifiable etiology.
An infiltrative mass with broad base, irregular borders, and 'cauliflower' morphology in the right atrium combined with marked hyperintense signal due to intratumoral hemorrhage on T1-weighted sequences is the most important diagnostic finding of cardiac angiosarcoma. This triple combination (right atrium dominant location + T1 hyperintensity + hemorrhagic pericardial effusion) is highly specific for angiosarcoma and plays a critical role in differentiation from other cardiac tumors (myxoma, lymphoma, metastasis). Heterogeneous enhancement pattern and pericardial invasion on contrast-enhanced imaging strengthen the diagnosis.
On T1-weighted sequences, cardiac angiosarcoma shows heterogeneous signal; markedly hyperintense areas reflect intratumoral hemorrhage (subacute methemoglobin). This T1 bright signal is the most characteristic MR finding of angiosarcoma and is critically important for differentiation from other cardiac masses. When the 'cauliflower'-like irregular morphology and hemorrhagic character are evaluated together, angiosarcoma should be strongly considered. Non-hemorrhagic solid areas show isointense or slightly hyperintense signal to myocardium. Pericardial effusion may also be hyperintense on T1 — hemorrhagic effusion.
Report Sentence
Infiltrative mass in the right atrium with heterogeneous signal containing focal hyperintense areas on T1-weighted sequences, with signal changes due to intratumoral hemorrhage consistent with angiosarcoma.
On T2-weighted sequences, angiosarcoma shows heterogeneous signal. Solid tumor component gives intermediate-to-high T2 signal, while hemorrhagic areas appear with various signal characteristics: acute hemorrhage (deoxyhemoglobin) shows low T2 signal, subacute hemorrhage (intracellular methemoglobin) shows low signal, late subacute (extracellular methemoglobin) shows high signal. Necrotic and cystic areas are T2 hyperintense. Marked T2 signal loss (blooming) is seen in chronic hemorrhage foci with hemosiderin deposition. Pericardial effusion is generally T2 hyperintense but hemorrhagic component may give mixed signal.
Report Sentence
Markedly heterogeneous signal in the right atrial mass on T2-weighted sequences, consistent with hemorrhage products at different stages.
On contrast-enhanced MR, angiosarcoma shows heterogeneous, intense enhancement. Solid vascular areas enhance rapidly and prominently, while hemorrhagic, necrotic, and cystic areas show no enhancement — creating the 'cauliflower'-like heterogeneous morphology. 'Sunray' pattern — radial contrast enhancement spreading from tumor center to periphery — may be seen in some cases. Nodular pericardial thickening and enhancement indicates pericardial invasion. Extension from right atrial wall to mediastinum and great vessel invasion are best assessed on contrast-enhanced imaging.
Report Sentence
Heterogeneous enhancement in the right atrial mass on contrast-enhanced imaging with non-enhancing areas of hemorrhage/necrosis and intensely enhancing solid component, consistent with angiosarcoma.
On contrast-enhanced CT, a broad-based, irregularly bordered, lobulated infiltrative mass is seen in the right atrium. Shows heterogeneous enhancement — solid vascular areas enhance intensely while hemorrhagic/necrotic areas remain low density. Pericardial effusion is usually present and may be high density (hemorrhagic — >25-30 HU). Nodular pericardial thickening indicates pericardial invasion. Tumor extension to mediastinum, great vessel invasion, and pulmonary metastases are rapidly assessed on CT. ECG-gated CT reduces motion artifacts.
Report Sentence
Heterogeneously enhancing infiltrative mass in the right atrium with hemorrhagic pericardial effusion on contrast-enhanced CT, consistent with angiosarcoma.
On FDG PET-CT, cardiac angiosarcoma shows intense FDG uptake (SUVmax usually >10). As a high-grade malignant tumor, it has increased glycolytic activity. Heterogeneous uptake pattern — solid viable areas show intense, necrotic/hemorrhagic areas show low uptake. PET-CT is critically important for staging: superior to anatomical imaging for detecting lung, liver, bone metastases. SUV changes in treatment response assessment (post-chemotherapy) provide important prognostic information. Physiological myocardial FDG uptake may be confounding — myocardial suppression protocol (prolonged fasting, high-fat diet) is recommended.
Report Sentence
Intense FDG uptake (SUVmax: XX) in the right atrial mass on FDG PET-CT, consistent with high-grade malignant tumor.
On echocardiography, a broad-based, heterogeneous echogenicity, irregularly bordered infiltrative mass is seen in the right atrium. The mass originates from the right atrial free wall and protrudes into the atrial lumen. Pericardial effusion usually accompanies — hemorrhagic effusion may be seen with echogenic particles (fibrin strands, blood clot). Tricuspid valve obstruction or inferior vena cava narrowing may be observed. Contrast echocardiography (microbubbles) can demonstrate vascular perfusion and aids differentiation from thrombus. TEE provides higher resolution than TTE.
Report Sentence
Broad-based infiltrative mass in the right atrium with pericardial effusion containing echogenic particles on echocardiography, consistent with malignant tumor.
Criteria
Right atrium dominant (80%), broad-based infiltrative, T1 hyperintense hemorrhagic mass, pericardial effusion, mediastinal invasion
Distinct Features
Most common form. Originates from right atrial free wall. Hemorrhagic character is prominent. Can present emergently with pericardial tamponade. Pulmonary metastasis common at diagnosis. Worst prognosis — median survival 6-9 months.
Criteria
Left atrial location (15-20%), pulmonary vein obstruction findings, left-sided heart failure symptoms, mitral valve obstruction
Distinct Features
Less common. Can be confused with myxoma but broad base, invasive character, and T1 hyperintensity help differentiation. Presents with pulmonary vein narrowing and left heart failure symptoms. Systemic embolization risk (pulmonary embolization in right atrial type).
Criteria
Form originating from pericardium or with dominant pericardial involvement, massive hemorrhagic effusion, pericardial thickening and nodularity, constrictive pericardial physiology
Distinct Features
Constrictive physiology may develop with pericardial dominant involvement. Massive hemorrhagic effusion can cause recurrent tamponade episodes. Nodular pericardial thickening and enhancement on cardiac MR is a diagnostic clue. Pericardiectomy is important to assess resectability. Requires differential diagnosis with pericardial mesothelioma.
Distinguishing Feature
Cardiac lymphoma infiltrates multiple chambers, shows near-homogeneous enhancement, and is isointense-to-hypointense on T1 (hemorrhage is rare). Shows diffusion restriction. Angiosarcoma is right atrium dominant, T1 hyperintense (hemorrhage), heterogeneously enhancing, and causes pericardial effusion. Lymphoma encases coronary vessels without occlusion — angiosarcoma invades.
Distinguishing Feature
Myxoma is dominant in left atrium (75%), pedunculated, mobile mass; isointense to myocardium on T1 (hemorrhage rare). Angiosarcoma is right atrium dominant, broad-based, immobile, and T1 hyperintense. Myxoma is well-defined and non-invasive; angiosarcoma is infiltrative and invasive. Pericardial effusion is very common in angiosarcoma, rare in myxoma.
Distinguishing Feature
Cardiac metastasis occurs with known primary malignancy, usually multiple, pericardial dominant involvement. Angiosarcoma is a primary tumor presenting as dominant solitary mass in right atrium. Metastasis is usually isointense on T1 (except melanoma metastasis — melanin hyperintense). Known primary malignancy history is the critical differentiating point.
Urgency
emergentManagement
surgical-plus-chemotherapyBiopsy
NeededFollow-up
Cerrahi ve kemoterapi sonrası 3 aylık aralıklarla MR + BT toraks takibi. Prognoz kötü — medyan sağkalım 6-12 ay.Cardiac angiosarcoma is an oncological emergency. Most patients have advanced disease at diagnosis. Hemorrhagic pericardial effusion and tamponade require emergent pericardial drainage. Diagnosis is made with histopathological confirmation — endomyocardial biopsy or surgical biopsy. Treatment requires multimodal approach: surgical resection (R0 resection critical for prognosis), neoadjuvant/adjuvant chemotherapy (doxorubicin-based), and radiotherapy in appropriate cases. Complete resection is possible in less than 50% of cases — tumor invasion of great vessels and coronary arteries frequently poses an obstacle. Heart transplantation has been evaluated in selected cases but is controversial due to high recurrence rate. Novel targeted therapies (VEGF inhibitors — pazopanib) and immunotherapy are being investigated. Prognosis is extremely poor — median survival 6-12 months, 5-year survival below 10%.
Cardiac angiosarcoma is the most common primary malignant cardiac tumor with extremely poor prognosis (median survival 6-12 months). At diagnosis, most patients have pericardial invasion or distant metastasis (lung most common). It can present with right heart failure, hemorrhagic pericardial tamponade, or superior vena cava syndrome. Surgical resection + adjuvant chemotherapy/radiotherapy is performed but complete resection is often not possible. Early diagnosis and staging with MRI is vital. Cardiac angiosarcoma must be considered in the differential of patients presenting with hemorrhagic pericardial effusion.